Antimicrobial peptides are a diverse family of small, mostly cationic polypeptides that kill bacteria, fungi and even some enveloped viruses, while chemokines are a group of mostly cationic small proteins that induce directed migration of leukocytes through interactions with a group of seven transmembrane G protein-coupled receptors. Recent studies have shown that antimicrobial peptides and chemokines have substantially overlapping functions. Thus, while some antimicrobial peptides are chemotactic for leukocytes, some chemokines can kill a wide range of bacteria and fungi. Here, we examined a possible direct antiviral activity of chemokines against an enveloped virus HSV-1. Among 22 human chemokines examined, chemokines such as MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 showed a significant direct antiviral activity against HSV-1. It is intriguing that these chemokines are mostly known to be highly expressed by effector CD8 + T cells. The chemokines with a significant anti-HSV-1 activity commonly bound to HSV-1 virions via envelope glycoprotein gB. Electron microscopy revealed that the chemokines with a significant anti-HSV-1 activity were commonly capable of generating pores in the envelope of HSV-1. Thus, some chemokines have a significant direct antiviral activity against HSV-1 in vitro and may have a potential role in host defense against HSV-1 as a direct antiviral agent.
Introduction
Antimicrobial peptides, now known by >500 in number, are a diverse family of small, mostly cationic polypeptides that can kill bacteria, fungi, and even some enveloped viruses (Clayberger and Krensky, 2003; Daher et al., 1986; Ganz, 2003; Howell et al., 2004; Wang et al., 2003; Zasloff, 2002) . In mammals, such peptides are particularly abundant in the storage granules of phagocytic cells, cytotoxic granules of lymphocytes, and on the surface of mucosal tissues (Clayberger and Krensky, 2003; Ganz, 2003; Zasloff, 2002) . Chemokines are a group of mostly highly cationic small proteins that induce directed migration of various leukocytes through interactions with a group of seven transmembrane G protein-coupled receptors (Yoshie et al., 2001; Zlotnik and Yoshie, 2000) . Previous studies have shown that, like antimicrobial peptides, a number of chemokines have a potent direct killing activity against bacteria and fungi (Cole et al., 2001; Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002; Yang et al., 2003) . For example, we have shown that CCL28 (also known as mucosae-associated chemokine) (Pan et al., 2000; Wang et al., 2000) , which is selectively expressed at high levels in the mucosal tissues such as parotid glands, trachea, and colon, is secreted at high concentrations into lowsalt body fluids such as saliva and milk and has a significant antimicrobial activity against a wide range of bacteria and fungi (Hieshima et al., 2003) . Thus, CCL28 may have a dual role in mucosal immunity by recruiting IgA-producing plasma cells into the lamina propria of target mucosal tissues via its receptor CCR10 (Hieshima et al., 2003 Kunkel et al., 2003; Virology 350 (2006) 484 -492 www.elsevier.com/locate/yviro Lazarus et al., 2003; Wilson and Butcher, 2004) and also by exerting a broad-spectrum antimicrobial activity in secreted body fluids (Hieshima et al., 2003) . Conversely, some antimicrobial peptides have been shown to have a potent chemotactic activity for various blood leukocytes. For example, β-defensins attract dendritic cells and T cells through interaction with a chemokine receptor CCR6 (Yang et al., 1999) . LL-37 (the neutrophil granule-and epithelial cell-derived cathelicidin) attracts neutrophils, monocytes and T cells via formyl peptide receptor-like 1 (FPRL1), a serpentine receptor closely related to the chemokine receptors (De et al., 2000) . It is thus possible that 3.9 ± 0.6 0.6 ± 0.1
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>10 ND HSV-1 was treated at 37°C for 1 h with each chemokine serially diluted in PBS or 1/10 PBS containing 0.1% BSA. After that, viral titers were determined by a standard plaque assay on Vero cells to obtain IC 50 . Data represent mean ± SEM from at least three independent experiments. The results in this table are all from the recombinant chemokines obtained from R&D Systems. However, CCL2, CCL3, CCL4 and CCL5 obtained from Peprotech also gave essentially the same results (data not shown). chemokines and antimicrobial peptides have substantially overlapping functions. At present, it is not known whether such close functional relationships between chemokines and antimicrobial peptides have an evolutionary basis (Yang et al., 2002) . Given that some antimicrobial peptides have a direct antiviral activity against some enveloped viruses (Daher et al., 1986; Howell et al., 2004; Wang et al., 2003) , we asked whether some chemokines might have a direct antiviral activity against an enveloped virus. Here, we report that some chemokines, especially MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 that are all highly expressed by effector CD8 + T cells and NK cells (Catalfamo et al., 2004; Cocchi et al., 1995; Dorner et al., 2002 Dorner et al., , 2004 Stievano et al., 2003; Swanson et al., 2002; Wagner et al., 1998; Walzer et al., 2003) , can directly inactivate HSV-1 through binding to its envelope glycoprotein gB.
Results

Inactivation of HSV-1 by chemokines
We tested a total of 22 human chemokines for possible direct inactivation of HSV-1. HSV-1 was treated at 37°C for 1 h with each chemokine in PBS containing 0.1% BSA. Then, the viral titers were determined by a standard plaque assay on Vero cells. The results are summarized in Table 1 . As many as eight chemokines reduced HSV-1 titers with an IC 50 less than 10 μM. These were MIP-1α/CCL3, MIP-1β/CCL4, RANTES/CCL5, eotaxin/CCL11, PF-4/CXCL4, MIG/CXCL9, SDF-1/CXCL12 and lymphotactin/XCL1. In particular, MIP-1α/CCL3, MIP-1β/ CCL4 and RANTES/CCL5 were most potent in anti-HSV-1 activity. In control experiments, we observed no reduction in HSV-1 titers by pretreating Vero cells with 10 μM of each chemokine at 37°C for 1 h prior to plaque assays (data not shown). We also confirmed that each chemokine at 10 μM had no cytotoxic or other adverse effects on Vero cells by 24 h (data not shown). Thus, it was likely that some chemokines could directly inactivate HSV-1.
In general, a low-salt condition is essential for the bacteriocidal activity of antimicrobial peptides and chemokines (Cole et al., 2001; Ganz, 2003; Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002; Yang et al., 2003) . Therefore, we also determined IC 50 of the eight chemokines in 1/10 PBS. All the chemokines indeed showed a 4-to 6-fold reduction in IC 50 in a low salt condition (Table 1) . Nevertheless, the anti-HSV-1 activity of these chemokines was obviously less sensitive to salt concentrations than the usual antimicrobial activities of antimicrobial peptides and chemokines. This suggested that the binding of these chemokines to HSV-1 was not simply through the electrostatic interactions.
Direct binding of HSV-1 with anti-HSV-1 chemokines
If some chemokines were capable of directly inactivating HSV-1, these chemokines should be able to bind to HSV-1 virions. To test this, aliquots of HSV-1 were added to ELISA plates pre-coated with various chemokines and incubated at 37°C for 1 h. After washing, bound HSV-1 virions were recovered with a lysis buffer containing 0.5% NP-10 and measured by real-time PCR using primers specific for HSV-1 UL30 gene. As shown in Fig. 1A , HSV-1 virions indeed selectively bound to the chemokines that showed a significant anti-HSV-1 activity (Table 1) . To further examine the viral components that were involved in HSV-1 binding to RANTES/ Specific binding of gB-SEAP(His) 6 to the chemokines with anti-HSV-1 activity. gB-SEAP(His) 6 was applied at 20 nM to wells (50 μl/well) pre-coated without or with indicated chemokines and incubated at room temperature for 1 h. After washing, bound gB-SEAP(His) 6 was measured by the alkaline phosphatase activity and expressed as relative light units/s. For details, see Materials and methods. Each point represents ± SEM from three separate experiments. CCL5, we pretreated HSV-1 virions with MAbs to various HSV-1 envelope glycoproteins prior to the binding assay. As shown Fig. 1B , only anti-gB MAb significantly reduced binding of HSV-1 virions to RANTES/CCL5. Furthermore, as shown in Fig. 1C , the binding of HSV-1 virions to other seven anti-HSV-1 chemokines was also significantly reduced by anti-gB MAb. This suggested that the chemokines with anti-HSV-1 activity were commonly capable of binding to HSV-1 via gB.
Direct binding of recombinant HSV-1 gB to chemokines
To directly test the binding of HSV-1 gB to chemokines, we generated recombinant proteins consisting of the ectodomains of gB and gD fused with the secreted form of alkaline phosphatase (SEAP) tagged with six histidine residues (Imai et al., 1997) . The proteins were termed gB-SEAP(His) 6 and gD-SEAP(His) 6 , respectively. These recombinant proteins were applied to immobilized RANTES/CCL5 and bound proteins were measured by their SEAP activity. As shown in Fig. 2A(a) , gB-SEAP(His) 6 specifically bound to RANTES/CCL5. On the other hand, as shown in Fig. 2A(b) , gD-SEAP(His) 6 or control SEAP(His) 6 (not shown) did not bind to RANTES/CCL5 at all. Fig. 2B further shows that gB-SEAP(His) 6 also bound to other seven anti-HSV-1 chemokines but not to a negative control MCP-1/CCL2. Collectively, the chemokines with a significant anti-HSV-1 activity were commonly capable of binding to HSV-1 envelope glycoprotein gB.
Electron microscopic observation of HSV-1 virions treated with chemokines
To further gain an insight into the mode of action of chemokines with anti-HSV-1 activity on HSV-1 virions, we examined the morphology of HSV-1 virions treated with chemokines at 1 μM at 37°C for 1 h. Scanning electron microscopy (Fig. 3A) as well as transmission electron microscopy ( Fig. 3B ) revealed that the majority of viral particles treated with PBS alone or with MCP-1/CCL2 (the negative control) were intact, showing smooth surface, but damaged viral particles were dramatically increased in the virus samples treated with MIP-1α/CCL3, MIP-1β/CCL4, or RANTES/CCL5. In particular, virus particles with pores in the envelope were rarely seen in the control samples, but were dramatically increased in the samples treated with MIP-1α/ CCL3, MIP-1β/CCL4, or RANTES/CCL5. We therefore determined the frequencies of intact virions, virions with pores, and those severely damaged by counting more than 200 virions for each sample. The results are summarized in Fig. 3C . While about 70-80% of virions were intact in the samples treated with PBS or MCP-1/CCL2 (the negative control), only about 20% of virions were intact in the samples treated with MIP-1α/CCL3, MIP-1β/CCL4, or RANTES/CCL5. On the other hand, the frequencies of virions with pores and severely damaged virions were dramatically increased in the samples treated with MIP-1α/CCL3, MIP-1β/CCL4, or RANTES/ Fig. 3 . Analysis of HSV-1 treated with chemokines with electron microscopy. Aliquots of HSV-1 (15 μl, 1 × 10 11 PFU/ml) were treated without or with chemokines at 1 μM at 37°C for 1 h. After that, samples were appropriately processed and observed by scanning electron microscopy (A) and transmission electron microscopy (B). For details, see Materials and methods. Scale bars shown in control panels are 100 nm. Arrows indicate holes in the viral envelope. (C) Differential counting HSV-1 virions treated with chemokines. At least 200 virions were randomly examined from each sample to make a differential count of intact virions, virions with pores, and severely damaged virions. Each point represents mean ± SEM from three separate experiments.
CCL5. In particular, virions with pores were rarely seen in the samples treated with PBS alone or MCP-1/CCL2 (the negative control) but were dramatically increased to about 30-40% in the samples treated with MIP-1α/CCL3, MIP-1β/CCL4, or RANTES/CCL5. It is thus likely that anti-HSV-1 chemokines primarily generate pores in the HSV-1 envelope, which lead to further disintegration of the virus particles.
Discussion
Recent studies have demonstrated that chemokines and antimicrobial peptides have substantially overlapping functions, even though the evolutionary basis of these findings is not clear yet (Yang et al., 2002) . Thus, some chemokines have a significant antimicrobial activity against a wide range of bacteria and fungi (Cole et al., 2001; Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002; Yang et al., 2002 Yang et al., , 2003 , while some antimicrobial peptides are chemotactic for blood leukocytes (De et al., 2000; Yang et al., 1999) . Concerning antiviral activity, some antimicrobial peptides have been shown to directly inactivate some enveloped viruses (Daher et al., 1986; Howell et al., 2004; Wang et al., 2003) . Furthermore, α-defensins 1, 2 and 3 have been shown to inhibit replication, not entry, of HIV-1 in host cells (Chang et al., 2005; Zhang et al., 2002) . In the case of chemokines, MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/ CCL5 are known to be released by CD8 + T cells and suppress infection of R5-type HIV-1 by blocking the use of CCR5 coreceptor (Cocchi et al., 1995; D'Souza and Harden, 1996) . Similarly, SDF-1/CXCL12 is known to inhibit infection of X4type HIV-1 by blocking the use of CXCR4 coreceptor (Amara et al., 1997; Bleul et al., 1996; Oberlin et al., 1996) . However, it has not been shown whether any chemokines have a direct antiviral activity against some enveloped viruses. Here, we have demonstrated for the first time that some chemokines have a significant direct antiviral activity against an enveloped virus HSV-1 (Table 1) .
There are notable discrepancies between the chemokines with a potent anti-bacterial/fungal activity and those with a potent anti-HSV-1 activity. While chemokines such as IP-10/ CXCL10, MEC/CCL28 and LARC/CCL20 have been reported to be most potent in killing bacteria and fungi (Cole et al., 2001; Hieshima et al., 2003; Yang et al., 2003) , these chemokines are essentially negative for anti-HSV-1 activity in the present study (Table 1) . On the other hand, chemokines such as MIP-1α/ CCL3, MIP-1β/CCL4 and RANTES/CCL5 have been shown to be essentially negative for bactericidal activity (Cole et al., 2001; Hieshima et al., 2003; Yang et al., 2003) , but are most potent in anti-HSV-1 activity in the present study (Table 1) . Furthermore, even though cationic net charges are considered to be important for the antimicrobial activity of chemokines (Cole et al., 2001; Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002; Yang et al., 2003) , MIP-1α/CCL3 and MIP-1β/CCL4 are the exceptional chemokines that have anionic, not cationic, net charges. These discrepancies may be partly due to the different mechanisms of binding of chemokines to bacteria/fungi and to HSV-1 virions.
The main target structure of antimicrobial peptides in bacteria and fungi is the microbial plasma membrane, which, in contrast to that of mammalian cells, lacks cholesterol and relatively rich in negatively charged phospholipids (Ganz, 2003; Yang et al., 2002) . Thus, antimicrobial peptides, which are commonly highly cationic, selectively bind to the microbial plasma membranes by electrostatic interactions. After binding, these peptides are considered to penetrate the plasma membranes via their hydrophobic regions and to form a channel-like pore through self-aggregation within the plasma membrane (Ganz, 2003; Yang et al., 2002) . Chemokines, which are also mostly highly cationic, are likely to bind and damage the microbial plasma membrane essentially through the same mechanism (Hieshima et al., 2003; Yang et al., 2003) . In the case of enveloped viruses, however, the viral envelopes are primarily derived from the membranes of host cells. Thus, there would be no big differences in the charge or other basic properties between the viral envelopes and host cell membranes. This suggests that there should be some specific binding sites in the viral envelope for antimicrobial peptides and antiviral chemokines. In this context, Wang et al. have shown that retrocyclin, an ancestral hominid θ-defensin, protects human cells from infection by X4-and R5-strains of HIV-1 by binding to the glycoproteins such as gp120 and CD4 through a lectinlike activity (Wang et al., 2003) . Furthermore, Yasin et al. have shown that θ-defensin can also protect cells from infection by HSV-1 by binding to the viral glycoprotein gB (Yasin et al., 2004) . In the present study, we have shown that the chemokines with a significant anti-HSV-1 activity are also commonly capable of binding to HSV-1 gB (Figs. 1, 2) . HSV-1 gB is a viral envelope glycoprotein required for efficient virus entry and known to bind to heparan sulfate proteoglycan on the host cell surface (Laquerre et al., 1998) . Thus, some unique structural and biochemical features of gB may allow its efficient binding with θ-defensin and some chemokines. It remains to be seen which structural and biochemical features of gB account for its efficient binding with anti-HSV-1 chemokines. After binding to HSV-1 virions via gB, anti-HSV-1 chemokines apparently generate pores in the viral envelope (Fig. 3) . Thus, these chemokines may be inserted into the viral envelope by their hydrophobic regions and may form channel-like pores through self-aggregation within the membrane. This latter property, which is probably essential for the bactericidal activity of most antimicrobial peptides and chemokines, may require a low micromolar concentration for efficient self-polymerization within the microbial target membranes (Ganz, 2003; Yang et al., 2002) .
Another notable point with the chemokines with a significant anti-HSV-1 activity is that MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 are all known to be selectively expressed at high levels by effector CD8 + T cells and NK cells (Catalfamo et al., 2004; Cocchi et al., 1995; Dorner et al., 2002 Dorner et al., , 2004 Stievano et al., 2003; Swanson et al., 2002; Wagner et al., 1998; Walzer et al., 2003) . These are the exact types of cells known to play the major roles in innate and acquired immunity against viruses including HSV-1 (Bishop et al., 1984; Khanna et al., 2004) . Furthermore, Luster and his colleagues have reported that MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 are co-localized with perforin in the cytotoxic granules of CD8 + T cells and released via granular exocytosis (degranulation) upon TCR-stimulation of these cells (Wagner et al., 1998) . We have also shown that CD8 + T cells infiltrating in chronically inflamed tissues such as oral lichen planus and chronic active gastritis consistently carry RANTES/CCL5 proteins in cytoplasmic vesicles resembling the cytotoxic granules (Iijima et al., 2003; Ohtani et al., 2004) . Recently, however, Catalfamo et al. have reported that RANTES/CCL5, even though released via granule exocytosis, is stored in cytoplasmic vesicles different from those of perforin (Catalfamo et al., 2004) . At any rate, it is intriguing that the chemokines with the most potent anti-HSV-1 activity happen to be the ones that are commonly stored in the cytoplasmic granules of cytotoxic lymphocytes and rapidly released upon cell activation. Furthermore, CD8 + T cells and NK cells are known to form the immunological synapse with their targets (Lieberman, 2003) . This would allow the delivery of their granular contents onto the target surface at very high concentrations. If the targets are HSV-1 virions or HSV-1infected cells expressing HSV-1 gB on the surface, the released chemokines may directly attack the target virions or infected cells at high concentrations.
Yet another intriguing point possibly related to the present finding is that many herpesviruses are known to encode the viral chemokine receptors that bind and sequester many chemokines including MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 (Bodaghi et al., 1998; Murphy, 2001) . Currently, the viral chemokine receptors are considered to have a role in the viral escape strategy by capturing chemokines released from infected cells and thus preventing attraction of leukocytes toward infected cells (Bodaghi et al., 1998; Murphy, 2001) . However, another possibility suggested from the present study may be that the viral chemokine receptors are also meant to capture chemokines that potentially cause damages to virions and virus-infected cells and that are released in close vicinity and at high concentrations by effector CD8 + T cells and NK cells. Future studies are necessary to address such possibilities.
The antimicrobial activities of chemokines generally require much higher concentrations than their optimal concentrations for induction of leukocyte chemotaxis (Cole et al., 2001; Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002; Yang et al., 2003) . The levels of effective concentrations of chemokines for antimicrobial activity are, however, comparable to those of standard antimicrobial peptides and considered to be theoretically attainable at local infection sites (Cole et al., 2001; Hieshima et al., 2003; Krijgsveld et al., 2000; Starner et al., 2003; Tang et al., 2002; Yang et al., 2003) . The anti-HSV-1 activity of some chemokines shown here also requires relatively high concentrations (Table 1) . For example, the IC 50 of RANTES/CCL5 was 0.2-0.8 μM depending on the salt concentration. It was reported that the concentration of RANTES/CCL5 in activated CD8 + T cells could reach 1.6 μg/10 6 cells (Cocchi et al., 1995) . Based on this assumption, the calculated density of CD8 + T cells required for 0.2-0.8 μM of RANTES/CCL5 would be 1.3-5.0 × 10 6 cells/ml. Given the size of CD8 + T cells, these densities could be easily reached at local infection sites. In addition, there could be additive and/or synergistic effects among various effector molecules including chemokines (Tang et al., 2002) . We observed that the chemokines with anti-HSV-1 activity were at least additive in reducing HSV-1 titers (data not shown).
In conclusion, chemokines such as MIP-1α/CCL3, MIP-1β/ CCL4 and RANTES/CCL5 have a significant direct antiviral activity against HSV-1 at concentrations that are comparable to the known effective concentrations of potent antimicrobial peptides. They can commonly bind to HSV-1 envelope glycoprotein gB. Furthermore, MIP-1α/CCL3, MIP-1β/CCL4 and RANTES/CCL5 are all known to be stored in the cytoplasmic granules of effector CD8 + T cells and NK cells and can be released to the target surface at high concentrations upon cell activation. Thus, these chemokines may have a potential role in the host defense against HSV-1 as a direct antiviral agent. Studies using mice deficient of these chemokines or employing neutralizing antibodies against these chemokines may be useful to determine their actual contribution as a direct antiviral agent in vivo. It also remains to be seen whether some chemokines have a significant antiviral activity against other enveloped viruses such as cytomegalovirus and HIV-1.
Materials and methods
Chemokines and antibodies
All recombinant human chemokines were purchased from R&D systems (Minneapolis, MN). MCP-1/CCL2, MIP-1α/ CCL3, MIP-1β/CCL4 and RANTES/CCL5 were also purchased from PeproTech (Rocky Hill, NJ). Monoclonal antibodies against HSV-1 gB (10B7) and HSV-1 gG (7F5) were purchased from Virusys Corporation (Sykesvill, MD). Monoclonal antibodies against HSV-1 gC, HSV-1 gE and HSV-1 gP were purchased from ViroStat (Portland, ME). Monoclonal antibody against HSV-1 gD (1-I-9) was purchased from Chemicon (Temecula, CA). The McKrae strain of HSV-1 was propagated in Vero cells as described previously (Hill et al., 1987; Shirane et al., 2004) .
HSV-1
HSV-1 titers were determined by a standard plaque assay on Vero cells (Oakes et al., 1984; Shirane et al., 2004) . In brief, Vero cells were plated at 5 × 10 5 cells/well in 6-well plates and cultured overnight. HSV-1 samples were applied to wells and incubated at 37°C for 3 h for virus adsorption. After washing with phosphate buffered saline (PBS), cells were placed in 3 ml fresh medium and cultured at 37°C for 48 h. After washing, cells were fixed with 0.5% glutaraldehyde in PBS at room temperature for 10 min and stained with hematoxylin. Plaques were counted under an inverted microscope. To test direct inactivation of HSV-1 by chemokines, HSV-1 was incubated without or with test chemokines at 37°C for 1 h. After that, the plaque assays was done as described above. The final concentrations of chemokines in these plaque assays were diluted at least 200fold. In some experiments, Vero cells but not HSV-1 were pretreated with chemokines at 10 μM at 37°C for 1 h and washed before the plaque assay.
Binding of HSV-1 to immobilized chemokines
Chemokines (2 μg/ml in H 2 O) were immobilized onto ELISA plates at 37°C for 1 h. After washing, wells were blocked with PBS containing 1% bovine serum albumin (BSA) at 37°C for 30 min. After washing with water, wells were inoculated with 50 μl of HSV-1 (1 × 10 7 PFU/ml in PBS). In some experiments, HSV-1 was pretreated with anti-gB, anti-gC, anti-gD, anti-gE, anti-gG, anti-gP or control mouse IgG at 10 μg/ml at room temperature for 15 min. After incubation at 37°C for 1 h and washing with water, bound HSV-1 virions were lysed with 10 μl of 10 mM Tris-EDTA buffer (pH 7.8) containing 0.5% NP-40 at room temperature for 20 min. The lysed HSV-1 was diluted 10-fold with 10 mM Tris-EDTA buffer (pH 7.8) and was then measured by real-time PCR for HSV-1 UL30 gene as described previously (Marquart et al., 2003) . In brief, real-time PCR reactions were performed in a 25 μl mixture containing sample DNA (2 μl) and 2× master mix, and using TaqMan assay and 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Conditions for PCR were 50°C for 2 min, 95°C for 10 min, and 50 cycles of 95°C for 15 s (denaturation) and 60°C for 1 min (annealing/ extension). Copy numbers were determined by using a standard curve generated from control HSV-1. The primers used were +5′-CATCACCGACCCGAGGAGGAC-3′ and −5′-GGGC-CAGGCGCTTGTTGGTGTA-3′. The probe was 5′-CCGCC-GAACTGAGCAGACACCCGCGC-3′ that was labeled at the 5′-end with fluorescent reporter dye of 6-FAM. The primers and probe were purchased from Qiagen (Hilden, Germany). Quantification of HSV-1 was done by using Sequence Detector System (Applied Biosystems).
Binding of HSV-1 gB and gD to chemokines
We produced the ectodomain of HSV-1 glycoproteins gB and gD as fusion proteins with the secreted form of alkaline phosphatase (SEAP) tagged with six histidine residues (the (His) 6 tag) as described previously (Imai et al., 1997) . In brief, the coding sequences of gB ectodomain comprising 730 amino acids and gD ectodomain comprising 340 amino acids were amplified from pVF30 (Rosenthal et al., 1987) (generously provided by Dr. David C. Johnson, Oregon Health Sciences, University of Portland) and HSV-1 (McKrae) genomic DNA,respectively. The primers used were: +5′-CATCTCGAGCCCGTAGTCCCGCCATGC-3′ and −5′-CATTCTAGACATGGCGGCGTTGGCGTC-3′ for gB; +5′-CATCTCGAGGTGGTGCGTTCCGGTATG-3′ and −5′-CATTCTAGACATGTTGTTCGGGGTGGC-3′ for gD. The amplified coding sequences were subcloned into pDREF-SEAP(His) 6 -Hyg vector (Imai et al., 1997) , gene-rating pDREF-gB-SEAP(His) 6 -Hyg and pDREF-gD-SEAP (His) 6 -Hyg. 293/EBNA-1 cells were transiently transfected with these plasmids using Lipofectamine (Invitrogen, Carlsbad, CA). The fusion proteins termed gB-SEAP(His) 6 and gD-SEAP(His) 6 were purified from the culture supernatants using TARON metal affinity resin column (BD Biosciences, Mountain View, CA). The concentrations of gB-SEAP(His) 6 and gD-SEAP(His) 6 were determined by a sandwich-type enzyme-linked immunosorbent assay for alkaline phosphatase as described previously (Imai et al., 1997) . Purified placental alkaline phosphatase was purchased from Cosmo Bio (Tokyo, Japan) and used to generate the standard curve.
Chemokines (2 μg/ml in distilled water) were immobilized onto ELISA plates at 37°C for 1 h. After washing, plates were blocked with PBS containing 3% BSA at 37°C for 30 min. After washing, 50 μl of PBS containing 0.1% BSA and gB-SEAP(His) 6 , gD-SEAP(His) 6 or control SEAP(His) 6 was added to wells and incubated at room temperature for 1 h. After washing with PBS, bound gB-SEAP(His) 6 , gD-SEAP(His) 6 , and SEAP(His) 6 were measured by alkaline phosphatase enzymatic activity using Great EscApe Detection kit (BD Biosciences, Mountain View, CA) and expressed as relative light units/s.
Electron microscopy
Aliquots of HSV-1 (15 μl, 1 × 10 11 PFU/ml) were treated without or with chemokines at 1 μM at 37°C for 1 h. HSV-1 samples were fixed with 2% glutaraldehyde (Wako, Osaka, Japan) in PBS at 4°C overnight. For scanning electron microscopy, fixed HSV-1 samples were adsorbed to plastic cover slips, which had been treated with 0.1% poly-L-lysine (M. W. 22,100, Sigma-Aldrich, St. Luis, MO) for 5 min, washed with water and dried. After adsorption for 1 h, virions were further fixed with 2% glutaraldehyde in PBS, washed with water for 10 min twice, and post-fixed with 1% osmium tetraoxide (Nacalai-Tesque, Kyoto, Japan) in PBS at 4°C for 1 h. Samples were rinsed twice with water and dehydrated in a graded series of ethanol. After treatment with isoamyl acetate, samples were dried in a critical-point drying apparatus HCP-1 (Hitachi Koki, Tokyo, Japan) with liquid carbon dioxide. Dried samples were coated with 2-nm-thick platinum-paradium using a magnetron sputter coater E-1030 (Hitachi, Ibaraki, Japan). Samples were observed on a ultra-high resolution scanning electron microscope S-900 (Hitachi Koki) with accelerating voltage of 10 kV and actual magnifications ranging from ×100,000 to ×200,000. For transmission electron microscopy, fixed HSV-1 samples were diluted 1:4 with distilled water and spotted on a 150-A sheet mesh (Nissin EM, Tokyo, Japan), which had been coated with Formvar (Nissin EM), covered by 10 nm with evaporated carbon and made hydrophilic. Excess water was removed with filter paper and samples were negatively stained with 2% phosphotungstic acid. Excess fixative was removed with filter paper and samples were observed on a transmission electron microscope H7100 (Hitachi Koki) with accelerating voltage of 100 kV and a magnification of ×30,000.
